3-hydroxyflavone has been researched along with Chronic Kidney Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, L; Fu, P; Guo, F; Ma, L; Ren, Q; Tao, S; Zhang, C | 1 |
| Chen, M; Feng, L; Li, Z; Ou, C; Que, D; Wei, J; Yan, J; Yang, P; Zhang, X; Zhong, X | 1 |
2 other study(ies) available for 3-hydroxyflavone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Fisetin Improves Hyperuricemia-Induced Chronic Kidney Disease via Regulating Gut Microbiota-Mediated Tryptophan Metabolism and Aryl Hydrocarbon Receptor Activation.
Topics: Animals; Flavonols; Gastrointestinal Microbiome; Hyperuricemia; Mice; Receptors, Aryl Hydrocarbon; Renal Insufficiency, Chronic; Tryptophan | 2021 |
Dihydromyricetin ameliorates vascular calcification in chronic kidney disease by targeting AKT signaling.
Topics: Animals; Aorta; Aortic Diseases; Cells, Cultured; Disease Models, Animal; Flavonols; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Osteogenesis; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction; Vascular Calcification | 2021 |